Peplin's core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. PEP005 (ingenol mebutate), the lead compound in this proprietary technology, has demonstrated significant promise in phase II clinical trials as a topical agent for the treatment of actinic (solar) keratosis (AK), a common pre-cancerous lesion, and basal cell carcinoma (BCC), the most common form of skin cancer.